Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
Simulations Plus Community
NasdaqGS:SLP Community
3
Narratives
written by author
0
Comments
on narratives written by author
13
Fair Values set
on narratives written by author
Create a narrative
Simulations Plus
Popular
Undervalued
Overvalued
Community Investing Ideas
Simulations Plus
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Biopharma Budget And Pricing Will Curb Margins But Yield Promise
Key Takeaways Near-term revenue and profit growth are challenged by biopharma client budget constraints, delays, and industry consolidation despite strong long-term digitalization trends. Rising competition from open-source AI and global cost pressures threaten pricing power and margin expansion, even as new product features drive competitiveness.
View narrative
US$20.00
FV
33.7% undervalued
intrinsic discount
3.80%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 13 hours ago
author updated this narrative
Simulations Plus
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Key Takeaways The company anticipates notable earnings growth driven by increased revenue from QSP models and cross-selling post-acquisition units. A disciplined growth strategy aiming for higher EBITDA margins supports potential profitability amidst challenging macroeconomic conditions.
View narrative
US$25.33
FV
47.6% undervalued
intrinsic discount
8.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
about 14 hours ago
author updated this narrative
Simulations Plus
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
AI Integration And Cloud Platforms Will Unlock In Silico Opportunities
Key Takeaways Advanced AI integration and a unified operating model are set to boost innovation, accelerate software adoption, and drive sustained operational efficiencies. Expansion into new clinical trial and R&D verticals positions the company to capture larger, recurring revenue streams and long-term margin expansion globally.
View narrative
US$31.00
FV
57.2% undervalued
intrinsic discount
7.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 14 hours ago
author updated this narrative
Your Valuation for
SLP
SLP
Simulations Plus
Your Fair Value
US$
Current Price
US$13.27
32.9% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-63m
120m
2015
2018
2021
2024
2025
2027
2030
Revenue US$119.7m
Earnings US$16.2m
Advanced
Set Fair Value